- POSITIVE
Quarterly Revenue Panacea Biotec Jun-2026 Quarterly Revenue is Rs 141 Cr which is growth of 20.1% YoY.
- POSITIVE
Quarterly Net Profit Panacea Biotec Jun-2026 Quarterly Net Profit is Rs 1 Cr which is growth of 120.7% YoY.
NSE: PANACEABIO | BSE: 531349
Panacea Biotec Live Share Price Today, Share Analysis and Chart
aboutPanacea Biotec Ltd. is a research-based health management company with a significant global presence in the biotechnology and pharmaceutical sectors. With over 30 years of operational history, the company specializes in the development, manufacturing... Read More
313.25-12.65(-3.88%)
60,012
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Expensive UnderperformerThese stocks have average quality, expensive valuations and weak momentum. Investors should exercise cautionView SimilarEmbed DVM
Please subscribe to view forecaster data
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
8Positive14Negative
36.4%Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Panacea Biotec Stock Price Analysis
Day Price Range-3.9% 1 Day return | 313.2 (LTP) 311.1326 LowHigh |
|---|---|
Week Price Range0.6% 1 Week return | 313.2 (LTP) 304.8333.6 LowHigh |
Month Price Range-14.4% 1 Month return | 313.2 (LTP) 304.8366 LowHigh |
52 Week Price Range-28.5% 1 Year return | 313.2 (LTP) 292.4647 LowHigh |
Competitors/Peers
Revenue Mix
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Panacea Biotec quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140.8 | 116.7 | 103.2 | 94.4 | 117.2 | 74 | 111.8 | 80.1 | 60.7 | 96.8 | 98.3 | 96.7 | 92.8 | ||
Operating Exp. | 127.4 | 110.8 | 100.7 | 104.5 | 115.3 | 86.5 | 93 | 69.9 | 67.4 | 89.6 | 88.6 | 84.6 | 82.6 | |
Operating Profit | 7.3 | 0.3 | -1.4 | -13.7 | -3 | -18.6 | 15.4 | 6.7 | -10.5 | -9.2 | 6.6 | 10 | 6.8 | |
Operating Profit Margin % | 5.42% | 0.27% | -1.39% | -15.09% | -2.69% | -27.35% | 14.19% | 8.79% | -18.44% | -11.50% | 6.97% | 10.53% | 7.62% | |
Depr. | 4.5 | 4.2 | 4.9 | 4.9 | 4.8 | 4.9 | 5.2 | 5.1 | 5.1 | 5.1 | 5.2 | 5.3 | 5.4 | |
Interest | 6.9 | 6.3 | 7 | 5.9 | 6 | 4.6 | 3.9 | 3.8 | 3.2 | 3.4 | 3.4 | 3.6 | 3.5 | |
Profit Before Tax | 2 | -4.6 | -9.5 | -20.9 | -8.8 | -22 | 9.7 | 1.3 | -15 | -1.4 | 1.1 | 3.2 | 1.3 | |
Tax | 0.6 | -4.4 | -2.1 | -5.3 | -2.1 | -9.6 | 0 | -1.2 | 0 | 0.6 | ||||
Net Profit | 1.4 | -0.2 | -7.4 | -15.6 | -6.7 | -12.4 | 9.7 | 1.3 | -13.8 | -1.4 | 0.4 | 3.2 | 1.3 | |
EPS Adj. latest | 0.2 | -0 | -1.2 | -2.6 | -1.1 | -2 | 1.6 | 0.2 | -2.3 | -0.2 | 0.1 | 0.5 | 0.2 | |
Net profit TTM | -21.8 | -29.9 | -42.1 | -25.1 | -8.2 | -15.2 | -4.2 | -13.4 | -11.5 | 3.6 | -14.8 | -2 | -12 | |
Basic EPS TTM | -3.6 | -4.9 | -6.9 | -4.1 | -1.3 | -2.5 | -0.7 | -2.2 | -1.9 | 0.6 | -2.4 | -0.3 | -2 | |
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Panacea Biotec Technical Analysis
Panacea Biotec EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 321.0 |
|---|---|
| 10 Day | 327.4 |
| 12 Day | 329.9 |
| 20 Day | 339.2 |
| 26 Day | 345.4 |
|---|---|
| 50 Day | 367.3 |
| 100 Day | 391.1 |
| 200 Day | 400.1 |
Panacea Biotec Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202658.5%
Week54.9%
Month52.9%
Panacea Biotec Active Candlesticks
Hikkake Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Panacea Biotec Resistance and Support
316.77
Pivot
| First Resistance | 322.4 |
|---|---|
| Second Resistance | 331.6 |
| Third Resistance | 337.3 |
| First Support | 307.6 |
|---|---|
| Second Support | 301.9 |
| Third Support | 292.7 |
| Day RSI | 34.4 |
|---|---|
| Day MACD | -15.4 |
| Day MFI | 41.6 |
| Day MACD Signal Line | -14.2 |
Panacea Biotec Beta
| 1 Month | 0.9 |
|---|---|
| 1 Year | 1.0 |
| 3 Month | 0.8 |
|---|---|
| 3 Year | 1.0 |
Panacea Biotec Price Change Analysis
↓-14.4%
Over 1 Month
LowHigh
304.8366
↓-25.7%
Over 3 Months
LowHigh
304.8442.4
↓-13.2%
Over 6 Months
LowHigh
304.8647
↓-28.5%
Over 1 Year
LowHigh
292.4647
Panacea Biotec Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| MICROCURVES TRADING PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 626.61 | 965,723 | NSE |
| JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 626.12 | 380,507 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 618.84 | 417,995 | NSE |
| QE SECURITIES LLP | Bulk | Sell | 09 Jun 2026 | 621.49 | 400,548 | NSE |
| JUNOMONETA FINSOL PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 624 | 565,285 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 624.66 | 531,543 | NSE |
| CLT RESEARCH TECH PRIVATE LTD | Bulk | Sell | 09 Jun 2026 | 623.98 | 359,049 | NSE |
| ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 624.37 | 415,318 | NSE |
| DIPAN MEHTA COMMODITIES PRIVATE LIMITED | Bulk | Sell | 09 Jun 2026 | 625.17 | 420,933 | NSE |
| ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED | Bulk | Purchase | 09 Jun 2026 | 624.37 | 415,318 | NSE |
Panacea Biotec Corporate Actions
Panacea Biotec Dividend history and yield
Panacea Biotec dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Panacea Biotec dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
119 Sep 2011 | 0.75 | FINAL | - | Equity Share |
216 Sep 2010 | 0.25 | FINAL | - | Equity Share |
319 Sep 2008 | 1 | FINAL | - | Equity Share |
421 Sep 2007 | 1 | FINAL | - | Equity Share |
522 Sep 2006 | 1 | FINAL | - | Equity Share |
Panacea Biotec Board Meetings
Panacea Biotec past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
113 Aug 2026 | Quarterly Results | - |
230 May 2026 | Audited Results & Dividend | - |
329 May 2026 | Audited Results & Dividend | - |
411 Feb 2026 | Quarterly Results | - |
514 Nov 2025 | Quarterly Results | - |
Panacea Biotec Stock Split
Panacea Biotec stock split details, including announcement, record, and ex-split dates, along with the split ratios
#Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
103 Feb 2003 | 10 | 1 | 11 Feb 2003 |
Panacea Biotec Research Reports
Panacea Biotec research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 124 Oct 2017 | Rudra Shares and Stock Brokers Ltd | 310 | 240.3 | Buy | 29.01% | 30.36% |
Panacea Biotec Corporate Filings
Panacea Biotec BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 09 Oct 2026 | Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Please find attached newspaper copies regarding notice intimating the investors about the opening of special window for transfer and dematerialisation of physical shares | |
| 07 Oct 2026 | Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Please find attached certificate dated October 01, 2026 issued by Skyline Financial Services Pvt. Ltd. ("RTA") confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. | |
| 07 Oct 2026 | Panacea Biotec Ltd - 531349 - Details Of Shares Dematerialized During September 2026
Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 | Please find attached details of shares dematerialised during September 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 | |
| 01 Oct 2026 | Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Please find attached voting results of 42nd Annual General Meeting of the Company held on 29.09.2026 along with Scrutinizer''s Report | |
| 01 Oct 2026 | Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Outcome of AGM | Please find attached voting results of 42nd Annual General Meeting held on 29.09.2026 along with Scrutinizer''s Report |
Panacea Biotec Documents
Panacea Biotec Annual Reports
Panacea Biotec financials, including annual results, balance sheets, and cash flow statements.
Panacea Biotec Credit Ratings
Panacea Biotec credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
Panacea Biotec Investor Presentations
Panacea Biotec investor presentations, including business updates, financial insights, and strategic initiatives.
Panacea Biotec - Company Profile
Panacea Biotec Management Structure
Panacea Biotec management structure with salaries, total experience, and qualifications.
Panacea Biotec Board of Directors
Panacea Biotec Board of directors with salaries, total experience, and qualifications.
Website: www.panaceabiotec.com
About the company - Business Profile
Panacea Biotec Ltd. is a research-based health management company with a significant global presence in the biotechnology and pharmaceutical sectors. With over 30 years of operational history, the company specializes in the development, manufacturing, and marketing of high-end vaccines, pharmaceutical formulations, and nutrition products. It holds a leading position in the Indian vaccine market and exports its products to more than 50 countries globally. The company operates through a strong foundation of R&D-led innovation, maintaining cGMP-compliant facilities that are qualified by major global regulatory authorities such as the US FDA, WHO PQ, and EMA.
Key Points
- Key Facts: Founded in 1984 and headquartered in New Delhi, India. The company is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
- Operations and Resources: The company operates state-of-the-art manufacturing facilities located in Lalru (Punjab) and Baddi (Himachal Pradesh). It possesses multi-disciplinary R&D centers focused on drug discovery and development.
- Ownership and Management: Managed by a strong promoter group with Dr. Rajesh Jain serving as the Chairman and Managing Director.
- Market Significance: Serves critical healthcare sectors including pediatrics, diabetes, organ transplantation, and oncology. It plays a strategic role in global health, having reached over 50 million babies in Lower & Middle-Income Countries (LMICs) through its vaccines in the last three years.
- Sustainability and Innovation: In FY2025, the company avoided 165 tCo2 emissions and managed 74.78 tonnes of waste. It has high-level certifications, including a 3-star rating in safety by Vision Zero Rating System India 2024.
- Business Model: The business model is vertically integrated, focusing on niche products with high entry barriers. It excels in technology-intensive segments like recombinant vaccines and complex generics.
- Revenue Breakdown (FY2024-25):
- By Segment:
- Vaccines: ₹309.84 Crore
- Formulations: ₹249.25 Crore
- Total Revenue from Operations: ₹559.09 Crore (Consolidated).
- By Segment:
- Key Products and Advancements:
- Vaccines: Easyfive-TT (fully liquid hexavalent vaccine), Polprotect (IPV), and DengiAll (under development).
- Formulations: Immunosuppressants (Ciclosporin, Tacrolimus), Anticancer drugs (Paclitaxel), and Diabetes management products.
- Recent Launches: 23 new products across various therapeutic areas internationally in FY2025.
- Partnerships: Maintains strategic collaborations with global health organizations like WHO, UNICEF, and PAHO for vaccine supplies.
- Subsidiaries:
- Panacea Biotec Pharma Limited (PBPL) - Material subsidiary.
- Meyten Realtech Private Limited.
- Panacea Biotec (International) S.A., Switzerland.
- Panacea Biotec Germany GmbH.
- Strategic Initiatives: Current focus includes scaling up the nutrition and pharmaceutical formulations business, enhancing vaccine drug substance manufacturing capacities, and executing a robust pipeline of promising niche products to fuel long-term growth.
References